Selexipag is a first-in-class oral treatment option to reduce progression and hospitalization for pulmonary arterial hypertension.
Lauren J. VanHook, PharmD
Advertisement
Lauren J. VanHook is a PGY-1 pharmacy resident at John Dempsey Hospital/UConn Health, Farmington, Conn.
Articles by Lauren J. VanHook, PharmD
Advertisement
Latest Updated Articles
- FDA approves PAH treatment
Published: May 10th 2016 | Updated:
Advertisement
Advertisement
Trending on Drug Topics
1
The Rise in Supplement Use Calls for Pharmacist-Led Counseling, Education | NCPA 2025
2
Pneumococcal Diseases Require Constant Vaccine Development | NCPA 2025
3
Why Pharmacists Need to Put More Emphasis on Supplement Education | NCPA 2025
4
How Community Pharmacists Are Proactively Managing Patients’ Migraines | NCPA 2025
5
